Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin in Burning Mouth Syndrome
NCT02964728Phase 2Completed
- Sponsor
- Garibaldi-Centro Hospital
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, single-blind trial of botulinum toxin type A in burning mouth syndrome (BMS) (2 arms), sponsored by Garibaldi-Centro Hospital. Primary endpoint: Visual Analog Scale improvement at 1 month. Started Nov 2015; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
burning mouth syndrome (BMS)
Beyond the preview
Go deeper on NCT02964728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964728.